A Novel Iron-Based Supplement for Athletes Aged 18-25: Phase II

May 26, 2025 updated by: Jane Shearer, University of Calgary

Novel Iron-Based Supplement for Active Young Women With Sub-Optimal Iron

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study aims to assess the efficacy of a novel iron supplement in improving iron status, gut microbiome, and exercise performance in endurance-trained females.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Current iron supplements on the market are commonly associated with side effects including gastrointestinal distress, nausea, vomiting, and constipation. As a solution, we have developed a novel delivery system for iron supplementation that overcomes many of these limitations. The goal of this study is to assess the efficacy of a yeast-iron complex in improving iron status, gut microbiome, and exercise performance in young, endurance-trained females with sub-optimal iron status. Participants will consume 40mg of elemental iron every second day for 8 weeks. Before and after supplementation,participants will be assessed for exercise capacity (VO2max), iron status, and the current state of the gut microbiome. each week during supplementation, participants will complete a survey in in which they will report feelings of stress and recovery as well as gastrointestinal symptoms.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N4N1
        • University of Calgary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • cis-gendered female 18-25years old
  • sub-optimal iron status (ferritin ≤45mcg/ L)
  • At least 1 year past the age of menarche
  • Engage in moderate to vigorous endurance activity for at least 3 hours a week

Exclusion Criteria:

  • Supplemented with iron iron (>5mg/day), prebiotics, or probiotics in last 3 months
  • antibiotic use in last 3 months
  • - Energy availability >30 kcal/kg lean body mass

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Iron/yeast complex (FeSC)
Iron Supplement
Iron/yeast complex

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Iron Status
Time Frame: 4 weeks, 8 weeks
Ferritin
4 weeks, 8 weeks
Hemoglobin
Time Frame: 4 weeks, 8 weeks
Hemoglobin concentration
4 weeks, 8 weeks
Upper Gut Microbiome
Time Frame: 4 weeks, 8 weeks
SIMBA capsule
4 weeks, 8 weeks
Lower Gut microbiome
Time Frame: 4 weeks, 8 weeks
Fecal sample
4 weeks, 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise Capacity
Time Frame: 8 weeks
Oxygen Consumption (VO2max)
8 weeks
Hemoglobin Mass
Time Frame: 8 weeks
Carbon monoxide Rebreathing Technique
8 weeks
Gastrointestinal Symptoms 1
Time Frame: Weekly for 8 weeks
Gastrointestinal Symptoms Questionnaire
Weekly for 8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleepiness
Time Frame: Weekly for 8 weeks
Epworth Sleepiness scale
Weekly for 8 weeks
Gastrointestinal Symptoms 2
Time Frame: Weekly for 8 weeks
Patient-Reported Outcomes Measurement Information System
Weekly for 8 weeks
Stress and Recovery
Time Frame: Weekly for 8 weeks
The Recovery-Stress Questionnaire
Weekly for 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jane Shearer, PhD, University of Calgary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 17, 2024

Primary Completion (Actual)

March 12, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

February 12, 2024

First Submitted That Met QC Criteria

February 12, 2024

First Posted (Actual)

February 21, 2024

Study Record Updates

Last Update Posted (Actual)

May 30, 2025

Last Update Submitted That Met QC Criteria

May 26, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 23-0826

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron Deficiencies

Clinical Trials on FeSC

Subscribe